If it burns in a house smoke detectors alert us hence protecting life. A molecular smoke alert has now been developed by Dresden researchers for the TP53 gene, the most important human cancer gene. The alert goes on if the TP53 gene is mutated in cells. The molecular smoke detector works like a TP53 sensor, which monitors the correct function of the gene. A non-functional TP53 gene is going to activate the sensor, which initiates cell death.
Results from this study from the research team of Prof. Frank Buchholz are now published in the journal Nature Communications.
Cancer is caused by changes in the human genome. Mutations in oncogenes and in tumor suppressor genes accumulate unrecognized over time and lead to uncontrolled cell proliferation eventually. In 50% of all human tumors the tumor suppressor gene TP53 is no longer functional being the most frequently mutated cancer gene. TU Dresden-Scientists from the University Cancer Center UCC at the University Hospital Carl Gustav Carus, the National Center for Tumor Diseases NCT Dresden and the German Cancer Consortium DKTK Dresden concluded that the formation of a TP53 sensor could suppress tumor formation at a very early stage.
To achieve this they designed a genetic element that makes cell function dependent on normal TP53. If the TP53 function is interrupted, the sensor gets activated and initiates cell death. “We treat cancer cells long after they have gone through the transformation process,” says Prof. Dr. Frank Buchholz describing the current situation. As a result, therapy is often too late to be able to eliminate all cancer cells in the body. Furthermore, due to additional mutations, therapy-resistant clones quickly emerge from some cancer cells.
“The TP53 sensor enables an active precocious intervention for the first time. Our results show that cells with TP53 mutations can be selectively detected and eliminated at an early stage. Hence, the transformation process is prevented.” The researchers plan to use their initial findings to develop new cancer diagnostics and to establish a protection system against cancer mutations in the long-term.
The Latest on: TP53 sensor
Balluff Offers New Way to Protect Sensor Faces from Impact Damage
on May 10, 2018 at 5:00 pm
Adding a face saver to a flush mount sensor can protect the sensor from impact damage and ... Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic S... […]
QuickLogic Announces EOS S3 LV (Low Voltage) Voice and Sensor Processing Platform
on March 25, 2018 at 5:00 pm
"The EOS S3 voice and sensor processing platform has always featured industry ... From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndrome... […]
Scientists develop a sensor for the most important human cancer gene
on November 13, 2017 at 4:00 pm
the most important human cancer gene. The alert goes on if the TP53 gene is mutated in cells. The molecular smoke detector works like a TP53 sensor, which monitors the correct function of the gene. A ... […]
Competing memories of mitogen and p53 signalling control cell-cycle entry
on October 4, 2017 at 12:51 pm
The number of times an article has been cited by individual mainstream news sources, blog post, or member of Google+ along with a link to the original article or post. News articles, blog posts and Go... […]
Stress wakes up sleeping herpes viruses – but how?
on February 23, 2016 at 3:59 pm
Hiding their DNA genome inside the nuclei of the infected cells, the herpes viruses establish a lifelong infection in ... stresses all lead to the activation of a set of cellular "stress sensor" prote... […]
Single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe for the detection of rare mutations
on January 10, 2007 at 4:00 pm
The protocol uses a peptide nucleic acid (PNA) as both PCR clamp and sensor probe. The PNA probe binds tightly to perfectly matched wild-type DNA template but not to mismatched mutant DNA sequences, w... […]
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
on February 5, 2004 at 4:00 pm
1 Department of Discovery Oncology, Roche Research Center, Hoffmann–La Roche, Inc., Nutley, NJ 07110, USA. 2 Department of Chemistry, Roche Research Center, Hoffmann–La Roche, Inc., Nutley, NJ 07110, ... […]
via Google News and Bing News